Why is it important to perform comprehensive molecular testing in non-small cell lung cancer to look beyond the obvious mutations? Which biomarker tests are best and when should testing be performed?
In this podcast episode, you’ll hear Prof. Mark Socinski (medical oncologist) and Prof. Frédérique Penault-Llorca (pathologist) discuss why perseverance with molecular testing pays off in non-small cell lung cancer (NSCLC).
As the conversation unfolds, the experts explain why it’s so important to identify genetic alterations in NSCLC, which biomarker testing approaches should be considered standard of care, and the importance of close collaboration with the pathologist and other members of the multidisciplinary team for optimal patient care.
Prefer to listen on the go?
Get the podcast audio of the experts in conversation and download the full transcript on the COR2ED website:
[ Ссылка ]
Or listen on your usual podcast platform:
Spotify: [ Ссылка ]
Apple:
[ Ссылка ]
The medical experts in this podcast are expressing their own views and not those of COR2ED, supporters, or their institution. This podcast is supported by an Independent Medical Education Grant from Bayer. This podcast is developed by cor2ed.com.
